Envelope protein E1 as vaccine target for western equine encephalitis virus

Vaccine

Volumn 29, Issue 4, 2011, Pages 813-820

  Swayze, Richard D ^a   Bhogal, Hardeep S ^a   Barabé, Nicole D ^a   McLaws, Lori J ^a   Wu, Josh Q H ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

Author keywords

E1 envelope protein; Vaccine; Western equine encephalitis virus

Indexed keywords

ADENOVIRUS VECTOR; GLYCOPROTEIN E1;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; T LYMPHOCYTE; VIRUS INFECTION; WESTERN EQUINE ENCEPHALITIS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENCEPHALITIS VIRUS, WESTERN EQUINE; ENCEPHALOMYELITIS, EQUINE; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLAQUE ASSAY; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 78650558264     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.009     Document Type: Article

References (42)

1. Kuhn R.J. Togaviridae: the viruses and their replication. Fields virology 2007, 1000-1022. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
2. Netolitzky D.J., Schmaltz F.L., Parker M.D., Rayner G.A., Fisher G.R., Trent D.W., et al. Complete genomic RNA sequence of western equine encephalitis virus and expression of the structural genes. J Gen Virol 2000, 81:151-159.
3. Strauss J.H., Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994, 58:491-562.
4. Kielian M. Class II virus membrane fusion proteins. Virology 2006, 344:38-47.
5. Griffin D.E. Alphavirus. Fields virology 2007, 1023-1067. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
6. Meyer K.F., Haring C.M., Howitt B. The etiology of epizootic encephalomyelitis of horses in the San Joaquin Valley, 1930. Science 1931, 74:227-228.
7. Howitt B. Recovery of the virus of equine encephalomyelitis from the brain of a child. Science 1938, 88:455-456.
8. Calisher C.H. Medically important arboviruses of the United States and Canada. Clin Microbiol Rev 1994, 7:89-116.
9. Reisen W.K., Monath T.P. Western equine encephalomyelitis. The arboviruses: epidemiology and ecology 1989, 89-137. CRC Press, Boca Raton, FL. T.P. Monath (Ed.).
10. Forrester N.L., Kenney J.L., Deardorff E., Wang E., Weaver S.C. Western equine encephalitis submergence: lack of evidence for a decline in virus virulence. Virology 2008, 380:170-172.
11. Reisen W.K., Fang Y., Brault A.C. Limited interdecadal variation in mosquito (Diptera: Culicidae) and avian host competence for western equine encephalomyelitis virus (Togaviridae: Alphavirus). Am J Trop Med Hyg 2008, 78:681-686.
12. Reed D.S., Larsen T., Sullivan L.J., Lind C.M., Lackemeyer M.G., Pratt W.D., et al. Aerosol exposure to western equine encephalitis virus causes fever and encephalitis in cynomolgus macaques. J Infect Dis 2005, 192:1173-1182.
13. Hanson R.P., Sulkin S.E., Beuscher E.L., Hammon W.M., McKinney R.W., Work T.H. Arbovirus infections of laboratory workers. Extent of problem emphasizes the need for more effective measures to reduce hazards. Science 1967, 158:1283-1286.
14. Sidwell R.W., Smee D.F. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res 2003, 57:101-111.
15. Smith J.F., Davis K., Hart M.K., Ludwig G.V., McClain D.J., Parker M.D., et al. Viral encephalitides. Textbook of military medicine part I: warfare, weaponry, and the casualty. Medical aspects of chemical and biological warfare 1997, 561-589. Office of the Surgeon General, Department of the Army, United States of America, Washington, DC. Z. R. (Ed.).
16. Turell M.J., O'Guinn M.L., Parker M.D. Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates. Am J Trop Med Hyg 2003, 68:218-221.
17. Atasheva S., Wang E., Adams A.P., Plante K.S., Ni S., Taylor K., et al. Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus. Vaccine 2009, 27:4309-4319.
18. Nagata L.P., Hu W.G., Masri S.A., Rayner G.A., Schmaltz F.L., Das D., et al. Efficacy of DNA vaccination against western equine encephalitis virus infection. Vaccine 2005, 23:2280-2283.
19. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther 2009, 17:1333-1339.
20. Sullivan N.J., Geisbert T.W., Geisbert J.B., Shedlock D.J., Xu L., Lamoreaux L., et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006, 3:e177.
21. Pacheco J.M., Brum M.C., Moraes M.P., Golde W.T., Grubman M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 2005, 337:205-209.
22. Tan Y., Hackett N.R., Boyer J.L., Crystal R.G. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther 2003, 14:1673-1682.
23. Richardson J.S., Yao M.K., Tran K.N., Croyle M.A., Strong J.E., Feldmann H., et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009, 4:e5308.
24. Santosuosso M., McCormick S., Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005, 18:283-291.
25. Xu Q., Pichichero M.E., Simpson L.L., Elias M., Smith L.A., Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 2009, 16:367-375.
26. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
27. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
28. Harro C., Sun X., Stek J.E., Leavitt R.Y., Mehrotra D.V., Wang F., et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol 2009, 16:1285-1292.
29. Wu J.Q., Barabe N.D., Chau D., Wong C., Rayner G.R., Hu W.G., et al. Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine. Vaccine 2007, 25:4368-4375.
30. Barabe N.D., Rayner G.A., Christopher M.E., Nagata L.P., Wu J.Q. Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus. Vaccine 2007, 25:6271-6276.
31. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998, 95:2509-2514.
32. Mahy B.W.J., Kangro H.O. Virology methods manual 1996, Academic Press, San Diego.
33. Long M.C., Nagata L.P., Ludwig G.V., Alvi A.Z., Conley J.D., Bhatti A.R., et al. Construction and characterization of monoclonal antibodies against western equine encephalitis virus. Hybridoma 2000, 19:121-127.
34. Nagata L.P., Hu W.G., Parker M., Chau D., Rayner G.A., Schmaltz F.L., et al. Infectivity variation and genetic diversity among strains of western equine encephalitis virus. J Gen Virol 2006, 87:2353-2361.
35. Gauci P.J., Wu J.Q., Rayner G.A., Barabe N.D., Nagata L.P., Proll D.F. Identification of western equine encephalitis virus structural proteins that confer protection after DNA vaccination. Clin Vaccine Immunol 2010, 17:176-179.
36. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.S., Choppin J., Gahery-Segard H., et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002, 76:127-135.
37. Hodgson L.A., Ludwig G.V., Smith J.F. Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 1999, 17:1151-1160.
38. Das D., Gares S.L., Nagata L.P., Suresh M.R. Evaluation of a western equine encephalitis recombinant E1 protein for protective immunity and diagnostics. Antiviral Res 2004, 64:85-92.
39. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274:94-96.
40. Schmaljohn A.L., Johnson E.D., Dalrymple J.M., Cole G.A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 1982, 297:70-72.
41. Bangari D.S., Mittal S.K. Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 2006, 6:215-226.
42. Thacker E.E., Timares L., Matthews QL Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines 2009, 8:761-777.